SPONSOR
Institute of Hematology & Blood Diseases Hospital, China
Total Trials
22
Recruiting
22
Phases
Phase 2, Phase 1, Phase 4, Phase 2, Phase 3, EARLY_Phase 1
Conditions studied: CAR T-cell TherapyAutoimmune Hemolytic AnemiaBrain FunctionPsychological Well-BeingWaldenstrom MacroglobulinemiaAcute Lymphoblastic Leukemia ALLAllergic Transfusion ReactionCRS - Cytokine Release SyndromeMyelomaCytokine Release Syndrome
Institute of Hematology & Blood Diseases Hospital, China is a clinical research sponsor with 22 registered studies on ClinicalTrials.gov, of which 22 are actively recruiting participants. Research covers conditions including CAR T-cell Therapy, Autoimmune Hemolytic Anemia, Brain Function, Psychological Well-Being.
The trial portfolio spans Phase 2, Phase 1, Phase 4 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Institute of Hematology & Blood Diseases Hospital, China
How many clinical trials has Institute of Hematology & Blood Diseases Hospital, China sponsored?
ClinicalMetric currently tracks 22 clinical trials sponsored by Institute of Hematology & Blood Diseases Hospital, China, of which 22 are actively recruiting participants. These trials cover conditions including CAR T-cell Therapy, Autoimmune Hemolytic Anemia, Brain Function. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Institute of Hematology & Blood Diseases Hospital, China research focus on?
Institute of Hematology & Blood Diseases Hospital, China clinical trials span CAR T-cell Therapy, Autoimmune Hemolytic Anemia, Brain Function, Psychological Well-Being, Waldenstrom Macroglobulinemia, and additional conditions. The research pipeline includes Phase 2, Phase 1, Phase 4 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Institute of Hematology & Blood Diseases Hospital, China clinical trial?
To participate in a Institute of Hematology & Blood Diseases Hospital, China trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Institute of Hematology & Blood Diseases Hospital, China trials with current recruitment status updated daily.
Clinical Trials by Institute of Hematology & Blood Diseases Hospital, China
NCT06921980
Recruiting
Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia
CAR T-cell Therapy
NCT05914662 Phase 2
Recruiting
Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM
Waldenstrom Macroglobulinemia
NCT06608342 Phase 2
Recruiting
Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia ALL
NCT04688736 Phase 2
Recruiting
Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.
Allergic Transfusion Reaction
NCT07106671 Phase 2
Recruiting
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
CRS - Cytokine Release Syndrome
NCT07169487 Phase 1
Recruiting
Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study
Cytokine Release Syndrome
NCT07063225 Phase 2
Recruiting
Romiplostim N01 for Chemotherapy-induced Thrombocytopenia
Chemotherapy-induced Thrombocytopenia
NCT06658834 Phase 2
Recruiting
A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP
Primary Immune Thrombocytopenia
NCT06094881 Phase 2
Recruiting
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)
Immune Thrombocytopenia
NCT07406139 Phase 4
Recruiting
PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）
Hemophilia
NCT07315087 Phase 1
Recruiting
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
SLE - Systemic Lupus Erythematosus
NCT05660473 Phase 2
Recruiting
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT06607289
Recruiting
National Longitudinal Cohort of Hematological Diseases (NICHE) - CART
Hematological Malignancies
NCT06530550 Phase 2
Recruiting
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Lymphoma, T-Cell
NCT06244368 Phase 2
Recruiting
GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
Peripheral T Cell Lymphoma
NCT07441993 Phase 2
Recruiting
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
Marginal Zone Lymphoma
NCT06855810 Phase 2, Phase 3
Recruiting
Newly-diagnosed Pediatric T-cell ALL Protocol
Acute Lymphoblastic Leukemia
NCT07249073 EARLY_Phase 1
Recruiting
CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
Multiple Myeloma
NCT06481241
Recruiting
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
Philadelphia Chromosome Negative ALL
NCT06168851 Phase 2
Recruiting
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
Immune Thrombocytopenia
NCT07212335 EARLY_Phase 1
Recruiting
Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy
Immune Effector Cell Associated Hematotoxicity
NCT07019766
Recruiting
National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia
T-LGL Leukemia
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology